A reduction in the frequency of PD-1 expressing CD3+, CD4+, CD8+, Th1, Th1/17, and Th17 cells was seen in patients not experiencing vitiligo during therapy (Figure 2A). The gene discussed is CD4; the disease is vitiligo.